HTB South

2012

Volume 5 Number 4 October/December 2012 PDF

Volume 5 Number 4 October/December 2012

52nd International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9-12 September 2012, San Francisco

Study summaries from ICAAC 2012

Antiviral activity in vitro with S/GSK1265744

Efavirenz interaction studies with TB compounds bedaquiline and delamanid

19th IAS World AIDS Conference, 22–25 July 2012, Washington

HPTN-052: clinical advantages from earlier treatment

Hormonal contraception and the risk of HIV acquisition

Towards an HIV cure: Early developments reported at IAS, part 2

Online video interviews between researchers and activists

FDA approves Quad in US: price may prohibit UK access

Merck acquires CMX157 and EFdA and starts phase 2 study for new NNRTI

FDA approval of generic ARVs

Free HIV treatment in the UK for all, irrespective of residency status

Robin Hood Tax begins in France

Novartis case enters Indian Supreme court

India: Bayer stay order against compulsory licence denied

Increased incidence of ischemic stroke amongst HIV positive cohort

Discord controllers: characterising a new viremic controller phenotype

Ritonavir significantly increases exposure to colchicine (gout)

Ritonavir interaction with quinine is clinically insignificant but may warrant caution

Case report: fluticasone, fluconazole and ritonavir interactions

US guidelines include Stribild (Quad) as alternative rather than preferred option for treatment naive adults

IAS USA update adult ARV treatment guidelines

Costs for rapid TB test reduced by 40%

Jerome Horwitz dies at 93

Volume 5 Number 3 July-September 2012

HTB SUPPLEMENT: 2012 pipeline report

19th IAS World AIDS Conference, 22–25 July 2012, Washington

New booster – cobicistat as an alternative to ritonavir

Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study

Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients

In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials

Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks

Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients

Five-year results from raltegravir registrational studies

First report: atazanavir-related gallstones (cholelithiasis)

Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics

Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings

Update on new antiretrovirals for children and adolescents

Tenofovir prophylaxis for neonates

Efavirenz levels variable in children in the CHAPAS-3 study

Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART

High prevalence of peripheral neuropathy in children taking d4T in rural South Africa

BCG vaccination at birth induces CD4 cell activation in HIV exposed infants

Pharmacokinetics of old and new TB Drugs

High levels of maraviroc in rectal tissue fail to protect macaques from SIV transmission following rectal exposure

Mechanisms for circumcision to reduce HIV transmission in different penile tissue: target cell differences rather than keratinisation

Towards an HIV cure: Early developments in the field

14th International Workshop on Co-morbidities and Adverse Drug Reactions (IWCADR), 19–21 July 2012, Washington

Skeletal muscle toxicity and raltegravir

Proteinuria as a potential early marker of tenofovir-related renal toxicity

Earlier and greater comorbidities reported in HIV positive cohort

20th International HIV Drug Resistance Workshop, 9–13 June 2012, Sitges

In vitro resistance profile for BMS 986001

Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

Defective viral reservoir populations is common in patients on long-term suppressed ART

First case report of transmission with five-class resistance

New data on the Berlin patient: interpret with caution

Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only

FDA update to darunavir label: severe skin reactions

FDA approval of generic ARVs

EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines

US trade deal threatens access to medicines

Post navigation